GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.
Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.
For further information visit the "For Investors" section of the GeoPharma website at http://www.geopharmainc.com.
FORWARD LOOKING STATEMENTS
This press release may contain statements, which constitute forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including those regarding the company and its
subsidiaries' expectations, intentions, strategies and beliefs pertaining
to future performance. All statements contained herein are based upon
information available to the company's management as of the date hereof,
and actual results may vary based upon future events, both within and
without management's control. Important factors that could cause such
differences are described in the company's periodic filings with the
Securities and Exchange Commission.
GAAP FINANCIAL TABLES FOLLOW
GEOPHARMA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
Three Months Ended Nine Months Ended
|SOURCE GeoPharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved